SNGX - Soligenix, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.9000
0.0000 (0.00%)
At close: 3:37PM EDT
Stock chart is not supported by your current browser
Previous Close0.9000
Open0.8721
Bid0.0000 x 1100
Ask0.0000 x 800
Day's Range0.8600 - 0.9000
52 Week Range0.6500 - 1.3900
Volume16,713
Avg. Volume153,516
Market Cap18.27M
Beta (3Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.4870
Earnings DateNov 7, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.63
Trade prices are not sourced from all markets
  • Newsfile

    Soligenix's SGX942 On Track To Fill Unmet Medical Need; Targeting Oral Mucositis In Patients With Head and Neck Cancer

    Miami Beach, Florida--(Newsfile Corp. - October 3, 2019) - Soligenix (NASDAQ: SNGX) is nearing the release of its topline data for its late-stage Phase 3, DOM-INNATE trial to treat oral mucositis in patients with head and neck cancer, an unmet medical need. And, as the release date approaches, investors may be looking for any clue they can get as to how the drug is performing. That clue, incidentally, may have been provided by ...

  • PR Newswire

    Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada

    PRINCETON, N.J., Oct. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation to review the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the Global Chinese Financial Forum (GCFF) Conference on Saturday, October 5, 2019 at 11:55 am Pacific Time. The event will take place at Vancouver Executive Hotel, Vancouver, BC, Canada.

  • PR Newswire

    Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning

    Industry veteran brings extensive experience leading business development PRINCETON, N.J. , Sept. 16, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

  • PR Newswire

    Soligenix Appoints Jonathan Guarino as Chief Financial Officer

    PRINCETON, N.J., Sept. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has appointed Jonathan Guarino, as its Senior Vice President and Chief Financial Officer.  Mr. Guarino has over 20 years of diverse experience in the financial and strategic management of emerging growth and commercial companies, including in the life sciences industry.

  • PR Newswire

    Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

    PRINCETON, N.J., Aug. 29, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company's two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the RHK Capital 2019 Disruptive Growth Conference on Wednesday, September 4, 2019 at 9:20 AM EDT. The event will take place at 599 Lexington Avenue, 22nd floor, New York City.

  • Zacks Small Cap Research

    SNGX: Q&A on SGX942 Phase 3 Trial Interim Analysis…

    On August 28, 2019, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrollment in the ongoing Phase 3 clinical trial of SGX942 in the treatment of oral mucositis in patients with head and neck cancer. The DMC recommended that approximately 70 additional subjects be randomized into the trial to maintain the 90% statistical power for the primary outcome, which will increase the study sample size from 190 to 260 subjects. The increase in study sample size was required to account for any potential variability observed in the Phase 3 trial that differs from the trials original design assumptions.

  • Benzinga

    The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines ...

  • PR Newswire

    Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer

    Final topline results remain on target for first half 2020 PRINCETON, N.J. , Aug. 28, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company ...

  • Zacks Small Cap Research

    SNGX: Interim Analysis for Phase 3 Oral Mucositis Trial Imminent

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • PR Newswire

    Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

    Exploring Dusquetide in Broader Populations PRINCETON, N.J. , Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

  • PR Newswire

    Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results

    PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "It is an exciting time for Soligenix. We are now approaching data read-out in two Phase 3 clinical programs.

  • Zacks Small Cap Research

    SNGX: What to Expect from the Upcoming Interim Analysis of SGX942

    Soligenix, Inc. (SNGX) is a biopharmaceutical company currently conducting two pivotal Phase 3 clinical trials with its lead development compounds. • SGX301 is in a Phase 3 trial for the treatment of cutaneous T cell lymphoma (CTCL). • SGX942 is in a Phase 3 clinical trial for the treatment of oral mucositis in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines

    PRINCETON, N.J. , July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • PR Newswire

    Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract

    SGX201 and OrbeShield® are proprietary oral formulations of BDP that function as mucosally delivered steroidal treatments for the GI tract while minimizing systemic steroid side effects, including risk of severe infection.  SGX201 utilizes an enteric coated tablet to deliver steroid to the distal GI tract, while OrbeShield® employs both immediate and delayed release, enteric-coated formulations to cover both the proximal and distal GI tract.  Due to the low systemic bioavailability of BDP, these formulations maximize anti-inflammatory steroid action at the site of injury, while minimizing common side effects of steroids, including immune suppression, enabling their use in expanded populations.

  • Zacks Small Cap Research

    SNGX: Multiple Important Catalysts on the Horizon…

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • PR Newswire

    Soligenix Announces Appointment of Diane L. Parks to its Board of Directors

    Strengthens marketing and commercial expertise PRINCETON, N.J. , July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

  • PR Newswire

    Soligenix to Present RiVax® Program at the 13ᵗʰ Annual CounterACT Network Research Symposium

    PRINCETON, N.J., June 13, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.  The presentation will be given at the upcoming 13th Annual CounterACT Network Research Symposium on June 18-20, 2019 to be held at the New York Academy of Sciences, NY.

  • PR Newswire

    Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents

    PRINCETON, N.J., May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years. Innate Defense Regulators (IDRs) regulate the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing.  IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy.

  • Zacks Small Cap Research

    SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results

    PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We have completed the approximate 90 subject enrollment necessary to support the interim efficacy analysis of our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. This interim analysis, to be conducted by the independent Data Monitoring Committee (DMC) for the trial, is anticipated to occur in September 2019.

  • Zacks Small Cap Research

    SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below.

  • PR Newswire

    Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

    PRINCETON, N.J., April 18, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has reached a significant milestone in the Phase 3 clinical study (the "DOM-INNATE" study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC). Patient enrollment is sufficient to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).